Your browser doesn't support javascript.
loading
Tumor budding as a risk factor for lymph node metastases in cutaneous squamous cell carcinoma: a systematic review and meta-analysis.
Gil-Pallares, Pedro; Gil-Pallares, Maria Eugenia; Navarro-Bielsa, Alba; Figueroa-Silva, Olalla; Taboada-Paz, Laura; Suárez-Peñaranda, José Manuel.
Afiliação
  • Gil-Pallares P; Department of Dermatology, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain.
  • Gil-Pallares ME; Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
  • Navarro-Bielsa A; Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland.
  • Figueroa-Silva O; Department of Dermatology, Miguel Servet University Hospital, Zaragoza, Spain.
  • Taboada-Paz L; Universidad de Zaragoza, Zaragoza, Spain.
  • Suárez-Peñaranda JM; Department of Dermatology, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain.
Clin Exp Dermatol ; 2024 Apr 30.
Article em En | MEDLINE | ID: mdl-38687870
ABSTRACT

BACKGROUND:

Current staging systems have limitations in stratifying high-risk cases of cutaneous squamous cell carcinoma (cSCC). Tumor budding (TB) has emerged as a potential prognostic factor in various cancers.

OBJECTIVES:

This systematic review and meta-analysis aimed to evaluate the prognostic significance of TB in predicting lymph node metastases (NM) in cSCC.

METHODS:

A comprehensive search of the PubMed, Web of Science, EMBASE, and Cochrane databases was conducted. Studies investigating the association of TB using a 5-bud cut-off and NM in cSCC were included. A meta-analysis was performed using odds ratios (OR) to evaluate the association between TB and NM.

RESULTS:

Six retrospective studies comprising 793 cSCC patients were included. The random-effects analysis showed a significant association between high TB (≥5 buds) and NM (OR = 13.29, 95% CI = 5.55; 31.86).

DISCUSSION:

Tumor budding is a promising histopathologic feature for predicting NM in cSCC. The results show a strong association between high TB and NM, supporting its utility as a risk factor for NM in cSCC. Its inclusion in clinical practice and cSCC staging might be helpful in the stratification of high-risk cases and guide optimal management strategies for each patient. However, further investigation is needed to determine standardized reporting guidelines for TB in cSCC.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article